IFG works with 550 producing advisors and generates about $325 million in annual revenue, said Dave Fischer, the company's co ...

According to the Crohn’s and Colitis Foundation, nearly 1 in every 100 Americans are diagnosed with inflammatory bowel ...

AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.

CEO Ritik Malhotra is leveraging Savvy Wealth's Fidelity partnership in offers to Commonwealth advisors, alongside ...

Spotify stock has been climbing ahead of the streaming music giant's first-quarter report due next Tuesday as investors ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

The stock market had huge weekly gains on Trump tariff hopes. Apple, Amazon, Meta are on tap, but so are a lot of stocks near ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...

AbbVie Inc (NYSE:ABBV) said Thursday that it is preparing for potential pharmaceutical sector tariffs, warning investors that trade headwinds could impact financial performance later this year. While ...

J&J’s guselkumab gets EU approval for ulcerative colitis, offering new hope for patients who don’t respond to current ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...

Get to know the trusted journalists, on-air hosts and anchors, reporters and writers, and editorial leaders who deliver ...